Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 73.3% in May

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 12,126 shares, a growth of 73.3% from the April 30th total of 6,999 shares. Based on an average daily trading volume, of 23,966 shares, the short-interest ratio is presently 0.5 days. Currently, 0.7% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BOLT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Rodman & Renshaw began coverage on Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and an average price target of $34.67.

Bolt Biotherapeutics Price Performance

Bolt Biotherapeutics stock traded up $0.13 during midday trading on Thursday, hitting $4.76. 2,467 shares of the company’s stock were exchanged, compared to its average volume of 25,873. The company has a market cap of $9.14 million, a P/E ratio of -0.29 and a beta of 1.12. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a 50-day moving average price of $4.77 and a two-hundred day moving average price of $5.09. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $7.35.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. On average, equities research analysts forecast that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of large investors have recently added to or reduced their stakes in BOLT. Renaissance Technologies LLC boosted its holdings in shares of Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares in the last quarter. T3 Companies LLC bought a new stake in Bolt Biotherapeutics in the 4th quarter worth approximately $208,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Bolt Biotherapeutics in the fourth quarter worth approximately $112,000. Susquehanna International Group LLP purchased a new stake in Bolt Biotherapeutics in the third quarter worth approximately $89,000. Finally, Shay Capital LLC bought a new position in Bolt Biotherapeutics during the third quarter valued at approximately $85,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.